Rapt Therapeutics Inc.
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Clinical Advances
Summary
RAPT Therapeutics, Inc. announced its financial results for the third quarter and nine months ended September 30, 2025, reporting a net loss of $17.6 million for Q3 2025, compared to $18.4 million in Q3 2024. The company also reported a net loss of $52.4 million for the first nine months of 2025, down from $76.6 million in the same period of 2024. RAPT completed a $250 million public offering in October 2025, and initiated a Phase 2b trial for ozureprubart in food allergy. The company plans to report additional data from clinical trials in the future.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement